此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

接受 CARv3-TEAM-E T 细胞治疗的受试者的长期随访

2026年9月28日 更新者:Marcela V. Maus, M.D.,Ph.D.

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.

研究概览

详细说明

This is a long-term safety and efficacy follow-up study for subjects who have been treated with CAR T cells in corresponding Phase I main studies that evaluated the safety and efficacy of CAR T cells in subjects.

No investigational treatment will be administered in this study.

The FDA (2020) recommends long-term follow up for subjects treated with gene therapy drug products to monitor for delayed adverse events (AEs), as well as durability of clinical response.

Therefore, after monitoring of subjects in the main studies has been completed (24 months after CAR T cells infusion, or <24 months after CAR T cells infusion if subject terminated early due to disease progression or due to discontinuing corresponding main study for any reason), subjects will be asked to participate in a long-term follow-up study (LTFU).

Subjects will be followed for up to 15 years following their last CAR T cells infusion in the corresponding main study.

研究类型

观察性的

注册 (估计的)

45

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Matthew J Frigault, MD
  • 电话号码:617-643-6175
  • 邮箱:mfrigault@mgb.org

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • 招聘中
        • Massachusetts General Hospital
        • 首席研究员:
          • Matthew J Frigault, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit

描述

Inclusion Criteria:

Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.

Subjects meeting the following criteria are eligible for study participation:

  • Provision of voluntary written informed consent by subject
  • CAR T cells were administered in HCC IRB or MGB IRB corresponding main study

Exclusion Criteria:

Subjects meeting the following criterion are to be excluded from study participation:

- Subject unable to comply with study requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
CAR T cells
  • Eligibility to participate on this study if enrolled on an HCC IRB or MGB IRB corresponding main study and received infusion of CAR T cells
  • The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol
  • Medical History/Physical Exam
  • Blood Test
  • Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.
  • Tumor biopsy.
  • Data Collection
  • Biobanking

CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol

Tumor Biopsy per protocol

Blood Test per protocol

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Survival
大体时间:1 month

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

1 month
Overall Survival
大体时间:6 months

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

6 months
Overall Survival
大体时间:12 months

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

12 months
Overall Survival
大体时间:24 months

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

24 months
Progresison Free Survival
大体时间:1 month

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

1 month
Progresison Free Survival
大体时间:6 months

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

6 months
Progresison Free Survival
大体时间:12 months

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

12 months
Progresison Free Survival
大体时间:24 months

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

24 months
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
大体时间:Up to 15 Years

An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases.

Up to 15 Years
New incidence of a hematologic disorder
大体时间:up to 15 years

An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases.

up to 15 years
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
大体时间:up to 15 years

NCI Common Terminology Criteria for Adverse Events (CTCAE)

up to 15 years
Vector-derived RCL
大体时间:baseline and in 3 months, 6 months, and annually up to 15 years

Archiving of samples for potential detection of vector-derived RCL. RCL testing will be monitored at the central RCL lab (Indiana University) by a suitable qPCR assay for detection of the lentiviral vector (VSV-g DNA).

baseline and in 3 months, 6 months, and annually up to 15 years
Assessment of CAR T cells persistence by VCN in peripheral blood
大体时间:baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years

VCN will be performed in DNA from whole blood to monitor for persistence of vector sequence

baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
Progression-free Survival
大体时间:From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment

The number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
Overall Survival
大体时间:From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years

The time from post-CAR T cells infusion to the date of death.

From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Matthew J Frigault, MD、Massachusetts General Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年8月7日

初级完成 (估计的)

2038年8月1日

研究完成 (估计的)

2039年8月1日

研究注册日期

首次提交

2021年8月23日

首先提交符合 QC 标准的

2021年8月23日

首次发布 (实际的)

2021年8月27日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The Harvard Cancer Consortium (HCC) encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共享时间框架

Data can be shared no earlier than 1 year following the date of publication

IPD 共享访问标准

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅